Literature DB >> 3790642

Nicotine exposure and tardive dyskinesia.

R Yassa, S Lal, A Korpassy, J Ally.   

Abstract

The prevalence of tardive dyskinesia (TD) in chronic psychiatric outpatients was significantly higher in smokers (46/85) than in nonsmokers (18/69) (p less than 0.001). This increased prevalence was associated with a significantly greater prescribed dose of neuroleptics in women, but not in men. Nicotine increases the synthesis and release of dopamine in the nigrostriatal pathway of animals. Such a mechanism may contribute to the higher prevalence of TD in smokers. The present findings suggest that smoking is a risk factor for the development of TD. A statistically significant association between smoking and TD, however, does not necessarily imply a cause-effect relationship. Treatment of TD with mecamylamine or other central nicotine antagonists merits investigation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3790642     DOI: 10.1016/0006-3223(87)90131-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

1.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 3.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 4.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

Review 5.  Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia.

Authors:  D G Kirch; A M Alho; R J Wyatt
Journal:  Cell Mol Neurobiol       Date:  1988-09       Impact factor: 5.046

Review 6.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 7.  Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics.

Authors:  L G Miller
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

8.  Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.

Authors:  J S Paulsen; M P Caligiuri; B Palmer; L A McAdams; D V Jeste
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

9.  Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.

Authors:  Siow-Ann Chong; Ene-Choo Tan; Chay Hoon Tan
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

10.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.